Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
More News related to BIIB
- Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
- Biogen Idec to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
More News related to Upgrades
- FDIC's Q3 Report Shows Profits Rose, But Troubled Loans Continued to Rise; "Problem List" Up to 552 and Deposit Insurance Fund $8.2B In the Hole
- Cramer Positive on Whirlpool (WHR)
- Despite Stabilizing Housing Market, Underwater Mortgages Pose Big Threat
- Nordic American (NAT) CEO Speaks with Cramer; Both Bullish on Company
- Massive Deficits Plague the U.S.
Jefferies & Co upgrades Biogen Idec (Nasdaq: BIIB) from Hold to Buy. Price target $50.
To see more analyst ratings on BIIB Click Here.
Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally.
Related Categories
UpgradesStocks Mentioned
+0.15Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
